Nucleome Therapeutics
PrivateLast Round
Series A
Oct 19, 2022
Total Funding Raised
$42.48M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Nucleome Therapeutics is a biotechnology company that decodes the non-coding genome to discover and develop first-in-class precision medicines for inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nucleome Therapeutics Comparables
Compare Nucleome Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Engine Biosciences | 81% | |
| Scenic Biotech | 77% | |
| Insitro | 76% |
Nucleome Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Oct 19, 2022 | ||||
| Seed | Jul 17, 2019 |
Key People
Founding team and executive leadership
Nucleome Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Oxford Science Enterprises | Series A, Spinoff |
| M Ventures | Series A |
| British Patient Capital | Series A |
| British Patient Capital | Series A |
| Oxford Science Enterprises | Series A, Seed |
| Pfizer Ventures | Series A |
| Johnson & Johnson Innovation - JJDC, Inc. | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 137% MoM.
- Jul 1, 2026
Lead molecule NTP464 advancing to Phase 1 trials.
Nucleome Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Nucleome Therapeutics's valuation, stock price, and market status.
Is Nucleome Therapeutics a public or private company?
Nucleome Therapeutics is a private company.
What is the current stock price of Nucleome Therapeutics?
Nucleome Therapeutics is a private company, so its shares have no public market price. Caplight tracks Nucleome Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Nucleome Therapeutics worth (valuation)?
Valuation information for Nucleome Therapeutics is not publicly available.
Can I buy Nucleome Therapeutics stock?
Nucleome Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Nucleome Therapeutics's last funding round?
Nucleome Therapeutics's most recent funding round was Series A on October 19, 2022.
Who are the main investors in Nucleome Therapeutics?
Key investors in Nucleome Therapeutics include M Ventures, Oxford Science Enterprises, M Ventures.
Will Nucleome Therapeutics IPO soon?
No public IPO plans have been announced for Nucleome Therapeutics.
How can I track Nucleome Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Nucleome Therapeutics's shares on secondary markets.